Manchester Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Manchester Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.54K	Buy	45 +29	+181%	+$1.69K	﹤0.01%	980
2025 Q4	$951	Buy	16 +1	+7%	+$54	﹤0.01%	1145
2025 Q3	$813	Hold	15	–	–	﹤0.01%	1162
2025 Q2	$825	Sell	15 -18	-55%	-$1.06K	﹤0.01%	1080
2025 Q1	$2.33K	Sell	33 -1	-3%	-$67	﹤0.01%	987
2024 Q4	$2.23K	Buy	34 +3	+10%	+$201	﹤0.01%	977
2024 Q3	$2.18K	Buy	31 +10	+48%	+$836	﹤0.01%	987
2024 Q2	$1.73K	Buy	+21	New	+$1.75K	﹤0.01%	965
2024 Q1	–	Sell	-6	Closed	-$579	–	1038
2023 Q4	$579	Buy	+6	New	+$531	﹤0.01%	899
2021 Q1	–	Sell	-15	Closed	-$1K	–	657
2020 Q4	$1K	Buy	15 +12	+400%	+$951	﹤0.01%	635
2020 Q3	$0	Buy	+3	New	+$304	﹤0.01%	561

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Manchester Capital Management's BMRN Position: Q1 2026 in Review

Manchester Capital Management increased its BioMarin Pharmaceuticals (BMRN) stake by 181% in Q1 2026, buying an estimated $1.69K and bringing the position to 45 shares worth $2.54K. The position accounts for ﹤0.01% of the portfolio, ranked #980.

Manchester Capital Management first reported a position in BMRN in Q3 2020 and has held it in 11 quarters since. 555 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Manchester Capital Management held 45 shares of BioMarin Pharmaceuticals worth $2.54K as of Q1 2026.
Manchester Capital Management bought 29 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $1.69K.
BioMarin Pharmaceuticals made up ﹤0.01% of Manchester Capital Management's portfolio in Q1 2026, its #980 holding.
Manchester Capital Management first reported a position in BioMarin Pharmaceuticals in Q3 2020 and has held it in 11 quarters since.
555 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Manchester Capital Management's 13F filing for Q1 2026, filed 11 May 2026.